Literature DB >> 22242044

A potential relationship between diffuse musculoskeletal pain and hypogonadism.

Jaclyn K Anderson1, Rebecca Tuetken, Valerie Hoffman.   

Abstract

Some men presenting with diffuse musculoskeletal pain have testosterone values below the normal range for their age. While scant evidence suggests that functional status in such men may improve with testosterone replacement therapy, there are currently no published studies evaluating a potential correlation between diffuse musculoskeletal pain and male hypogonadism. In a cohort of 45 hypogonadal men with diffuse musculoskeletal pain we found a negative correlation between the duration of pain in years and baseline total testosterone values. Although advancing age would theoretically predispose individuals to lower testosterone concentrations, age was not independently associated with baseline testosterone values, nor were any other variables we examined. At this time generalised screening of gonadal function for such men is not indicated. A prospective study would more clearly evaluate a potential relationship between diffuse musculoskeletal pain and testosterone values in men and might determine if testosterone replacement leads to any measurable improvement.

Entities:  

Year:  2010        PMID: 22242044      PMCID: PMC3027404          DOI: 10.1136/bcr.08.2009.2152

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  35 in total

Review 1.  Proof of the effect of testosterone on skeletal muscle.

Authors:  S Bhasin; L Woodhouse; T W Storer
Journal:  J Endocrinol       Date:  2001-07       Impact factor: 4.286

2.  Nonfunctional pituitary macroadenoma manifested as muscular symptoms.

Authors:  Akio Matsubara; Aki Tamura; Syunji Matsumura; Hitoshi Yokoya; Satoshi Maruyama; Kanao Kobayashi; Yukihiko Kawamoto; Jun Teishima; Mitsuhiro Seki; Tsuguru Usui
Journal:  Hiroshima J Med Sci       Date:  2006-12

3.  Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects.

Authors:  G Laakmann; C Schüle; T Baghai; E Waldvogel
Journal:  Psychoneuroendocrinology       Date:  1999-10       Impact factor: 4.905

4.  Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  S N Seidman; E Spatz; C Rizzo; S P Roose
Journal:  J Clin Psychiatry       Date:  2001-06       Impact factor: 4.384

5.  Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.

Authors:  T Ljung; A C Ahlberg; G Holm; P Friberg; B Andersson; E Eriksson; P Björntorp
Journal:  J Intern Med       Date:  2001-09       Impact factor: 8.989

6.  Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression.

Authors:  S N Seidman; J G Rabkin
Journal:  J Affect Disord       Date:  1998-03       Impact factor: 4.839

7.  Differential effects of neuroleptic agents on the pituitary-gonadal axis in men.

Authors:  W A Brown; T P Laughren; B Williams
Journal:  Arch Gen Psychiatry       Date:  1981-11

8.  Prolactin-releasing effect of buspirone in developing and adult male and female rats.

Authors:  P F Hockl; G S Diaz; C Libertun
Journal:  Proc Soc Exp Biol Med       Date:  1993-04

9.  Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort.

Authors:  M Hotopf; R Mayou; M Wadsworth; S Wessely
Journal:  Br J Psychiatry       Date:  1998-09       Impact factor: 9.319

10.  Clinical aspects of androgen deficiency in men.

Authors:  D P Nicholls; D C Anderson
Journal:  Andrologia       Date:  1982 Sep-Oct       Impact factor: 2.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.